SHIELD THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.05 GBX | -.--% |
|
-14.58% | -69.40% |
| May. 28 | NetScientific backs Wanda; Inspirit Energy wins deal | AN |
| May. 10 | Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 209.8 | 74.69 | 96.06 | 18.29 | 52.4 | 16.03 | - |
| Enterprise Value (EV) 1 | 205.7 | 71.78 | 84.1 | 18.29 | 52.4 | 38.89 | 36.46 |
| P/E ratio | -22.4 x | -31.8 x | -4.94 x | -0.41 x | -1.68 x | -0.88 x | 4.7 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 292 x | 7.19 x | 63.2 x | 4.09 x | 5.01 x | 0.66 x | 0.23 x |
| EV / Revenue | 286 x | 6.91 x | 55.4 x | 4.09 x | 5.01 x | 1.61 x | 0.51 x |
| EV / EBITDA | -32.1 x | 130 x | -4.74 x | -0.78 x | -2.17 x | -2.77 x | 3.88 x |
| EV / FCF | -38 x | -50.4 x | -4.92 x | - | - | -2.15 x | 114 x |
| FCF Yield | -2.63% | -1.98% | -20.3% | - | - | -46.5% | 0.87% |
| Price to Book | - | 2.47 x | 2.34 x | - | - | -2.85 x | - |
| Nbr of stocks (in thousands) | 117,189 | 117,620 | 215,874 | 259,388 | 782,056 | 782,056 | - |
| Reference price 2 | 1.790 | 0.6350 | 0.4450 | 0.0705 | 0.0670 | 0.0205 | 0.0205 |
| Announcement Date | 5/21/20 | 4/29/21 | 6/30/22 | 4/27/23 | 5/10/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.719 | 10.39 | 1.519 | 4.467 | 10.46 | 24.13 | 71.12 | - |
| EBITDA 1 | -6.414 | 0.551 | -17.74 | -23.34 | -24.18 | -14.06 | 9.408 | - |
| EBIT 1 | -9.035 | -2.154 | -19.95 | -25.71 | -25.04 | -14.92 | 2.57 | -3.37 |
| Operating Margin | -1,256.61% | -20.74% | -1,313.5% | -575.46% | -239.44% | -61.84% | 3.61% | - |
| Earnings before Tax (EBT) 1 | -9.066 | -1.886 | -19.56 | -40.08 | -25.87 | -17.52 | 5.069 | - |
| Net income 1 | -8.8 | -2.63 | -19.34 | -40.44 | -26.6 | -18.25 | 3.436 | - |
| Net margin | -1,223.92% | -25.32% | -1,272.94% | -905.4% | -254.44% | -75.63% | 4.83% | - |
| EPS 2 | -0.0800 | -0.0200 | -0.0900 | -0.1700 | -0.0400 | -0.0234 | 0.004360 | - |
| Free Cash Flow 1 | -5.416 | -1.423 | -17.11 | - | - | -18.07 | 0.3187 | - |
| FCF margin | -753.27% | -13.7% | -1,126.4% | - | - | -74.88% | 0.45% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 3.39% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | 9.27% | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 5/21/20 | 4/29/21 | 6/30/22 | 4/27/23 | 5/10/24 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2022 S1 | 2023 S1 |
|---|---|---|---|
| Net sales 1 | 8.919 | 2.031 | 4.334 |
| EBITDA | - | - | - |
| EBIT 1 | - | -11.72 | -11.54 |
| Operating Margin | - | -577.25% | -266.29% |
| Earnings before Tax (EBT) | - | - | - |
| Net income | - | - | - |
| Net margin | - | - | - |
| EPS | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 9/16/20 | 9/8/22 | 9/28/23 |
1GBP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 22.9 | 20.4 | - |
| Net Cash position 1 | 4.1 | 2.91 | 12 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -1.626 x | 2.171 x | - |
| Free Cash Flow 1 | -5.42 | -1.42 | -17.1 | - | - | -18.1 | 0.32 | - |
| ROE (net income / shareholders' equity) | - | -8.43% | -54.2% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.2600 | 0.1900 | - | - | -0.0100 | - | - |
| Cash Flow per Share 2 | -0.0300 | -0.0100 | -0.0800 | - | - | -0.0200 | 0.0100 | - |
| Capex 1 | 1.35 | 0.02 | 0.37 | - | - | 0.67 | 0.63 | 1.61 |
| Capex / Sales | 187.76% | 0.22% | 24.49% | - | - | 2.76% | 0.89% | - |
| Announcement Date | 5/21/20 | 4/29/21 | 6/30/22 | 4/27/23 | 5/10/24 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0205
GBP
Average target price
0.16
GBP
Spread / Average Target
+680.49%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -69.40% | 20.4M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- STX Stock
- Financials Shield Therapeutics plc
